Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GSK3915393 in Healthy Participants
NCT04604795Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3915393 in celiac disease (9 arms), sponsored by GSK. Primary endpoints: Number of Participants With All Non-serious Adverse Events and Serious Adverse Events up to 72 days, Number of Participants With Worst Case Chemistry/Hematology Results by PCI Criteria up to 72 days and 6 more. Started Nov 2020; status: completed.
02
Drugs
GSK3915393
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04604795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604795.